Kenia - Engels - Pharmacy and Poisons Board

sanofi-aventis kenya ltd p.o. box 20337-00200 - insulin glulisine - solution for injection in pre-filled pen - insulin glulisine 100iu/ml - insulins and analogues for injection fast-acting

Verenigde Staten - Engels - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz) - insulin glargine 300 u in 1 ml - toujeo is indicated to improve glycemic control in adults and pediatric patients 6 years of age and older with diabetes mellitus. limitations of use: toujeo is not recommended for the treatment of diabetic ketoacidosis. toujeo is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] . - in patients with hypersensitivity to insulin glargine or any excipients in toujeo [see warnings and precautions (5.5)] . risk summary published studies with use of insulin glargine during pregnancy have not reported a clear association with insulin glargine and adverse developmental outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dose of 0.2 unit/kg/day. overall, the effects of insulin glargine did not generally differ from those obser

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - insulin - parenteral liquid/solution/suspension - insulin hormone active 40.0 iu/ml - endocrine system - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - insulin deficiency

Canada - Engels - Health Canada

sanofi-aventis canada inc - insulin glulisine (recombinant dna origin) - solution - 100unit - insulin glulisine (recombinant dna origin) 100unit - insulins

Canada - Engels - Health Canada

sanofi-aventis canada inc - insulin glulisine (recombinant dna origin) - solution - 100unit - insulin glulisine (recombinant dna origin) 100unit - insulins

Canada - Engels - Health Canada

sanofi-aventis canada inc - insulin glulisine (recombinant dna origin) - solution - 100unit - insulin glulisine (recombinant dna origin) 100unit - insulins

Canada - Engels - Health Canada

sanofi-aventis canada inc - insulin glulisine (recombinant dna origin) - solution - 100unit - insulin glulisine (recombinant dna origin) 100unit - insulins

Ierland - Engels - HPRA (Health Products Regulatory Authority)

intervet ireland limited - insulin - suspension for injection - 40 international unit(s)/millilitre - insulin (pork) - cats, dogs - hormone

Australië - Engels - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 200 iu/ml - injection, solution - excipient ingredients: glycerol; zinc oxide; trometamol; water for injections; hydrochloric acid; sodium hydroxide; metacresol - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Europese Unie - Engels - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - diabetes mellitus - drugs used in diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.